Truist Financial has issued a research report reducing its price target for Albemarle Corporation (NYSE:ALB) from $260.00 to $245.00, maintaining a "buy" rating on the specialty chemicals company. Despite this reduction, Truist's objective suggests a potential upside of 106.64% from the current price. The consensus among various brokerages remains mixed but generally positive; Wells Fargo & Company raised its target to $200.00 with an "equal weight" rating, while UBS Group and Deutsche Bank Aktiengesellschaft increased their targets to $264.00 and $250.00 respectively, both assigning "buy" ratings. Conversely, Jefferies Financial Group lowered its target to $211.00, and Citigroup upgraded the stock to a "buy" with a $225.00 target. According to MarketBeat data, the stock currently holds an average rating of "Moderate Buy" with a consensus target price of $199.87. The aggregate analyst sentiment includes one Strong Buy, fifteen Buy ratings, ten Hold ratings, and one Sell rating. Albemarle recently reported quarterly earnings on May 6th, significantly outperforming expectations with earnings per share (EPS) of $2.95 compared to the consensus estimate of $1.24. The company generated revenue of $1.43 billion, surpassing the estimated $1.34 billion, representing a 32.7% year-over-year increase. However, the quarter showed a negative net margin of 5.00% and a return on equity of 5.22%. Analysts anticipate an average EPS of $12.95 for the current fiscal year. In corporate developments, CEO J Kent Masters sold 16,393 shares on May 15th at an average price of $183.72, totaling approximately $3.01 million. This transaction reduced his ownership stake by 15.78%, leaving him with 87,519 shares valued at roughly $16.08 million. Company insiders collectively own 0.42% of the stock. Institutional activity has seen significant movement in Albemarle shares over recent quarters. MH & Associates Securities Management Corp ADV acquired a new stake worth approximately $26,000 in the fourth quarter. BOKF NA expanded its holdings by 5,771.4% in the third quarter, now owning 411 shares valued at $33,000. Elyxium Wealth LLC and Torren Management LLC both established new positions worth approximately $34,000 and $38,000 respectively in the fourth quarter. EverSource Wealth Advisors LLC increased its stake by 536.7% in the second quarter, holding 573 shares valued at $36,000. Hedge funds and other institutional investors currently control 92.87% of the outstanding stock. Albemarle, founded in 1994 as a spin-off from Ethyl Corporation, is a global leader in specialty chemicals, primarily producing lithium for electric vehicle batteries, bromine products for oil and gas and water treatment, and catalysts for petroleum refining.